| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GW-405833 | CTRPv2 | pan-cancer | AAC | -0.0032 | 0.9 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | BRD-K30019337 | CTRPv2 | pan-cancer | AAC | -0.0073 | 0.9 |
| mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | -0.003 | 0.9 |
| mRNA | GSK2126458 | GDSC1000 | pan-cancer | AAC | -0.0027 | 0.9 |
| mRNA | BRD-K66532283 | CTRPv2 | pan-cancer | AAC | 0.0028 | 0.9 |
| mRNA | Tipifarnib | GDSC1000 | pan-cancer | AAC | -0.003 | 0.9 |
| mRNA | BRD-K52037352 | CTRPv2 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | PF-562271 | GDSC1000 | pan-cancer | AAC | -0.0028 | 0.9 |
| mRNA | BRD-K20514654 | CTRPv2 | pan-cancer | AAC | 0.0042 | 0.9 |